Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives $4.50 Consensus Price Target from Brokerages

Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) have been given an average rating of “Hold” by the six brokerages that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $4.50.

A number of research firms have recently commented on MIST. Weiss Ratings reissued a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research note on Wednesday, October 8th. Wells Fargo & Company assumed coverage on Milestone Pharmaceuticals in a report on Thursday, September 11th. They set an “overweight” rating and a $4.00 target price on the stock.

Milestone Pharmaceuticals Price Performance

Milestone Pharmaceuticals stock opened at $1.84 on Friday. Milestone Pharmaceuticals has a 12-month low of $0.63 and a 12-month high of $2.75. The stock has a market capitalization of $156.38 million, a PE ratio of -2.19 and a beta of 0.54. The firm has a 50 day simple moving average of $1.93 and a 200-day simple moving average of $1.70.

Milestone Pharmaceuticals (NASDAQ:MIST) last announced its earnings results on Tuesday, August 12th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.02). On average, analysts forecast that Milestone Pharmaceuticals will post -0.62 earnings per share for the current fiscal year.

Institutional Trading of Milestone Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Sapient Capital LLC bought a new stake in Milestone Pharmaceuticals during the third quarter worth approximately $25,000. Bay Rivers Group acquired a new stake in shares of Milestone Pharmaceuticals during the 2nd quarter valued at $28,000. Stephenson & Company Inc. bought a new stake in shares of Milestone Pharmaceuticals during the 3rd quarter worth $40,000. XTX Topco Ltd boosted its stake in shares of Milestone Pharmaceuticals by 52.7% during the 1st quarter. XTX Topco Ltd now owns 52,004 shares of the company’s stock worth $42,000 after acquiring an additional 17,950 shares in the last quarter. Finally, Creative Planning grew its holdings in shares of Milestone Pharmaceuticals by 74.6% in the 2nd quarter. Creative Planning now owns 23,410 shares of the company’s stock worth $45,000 after acquiring an additional 10,000 shares during the last quarter. 86.18% of the stock is currently owned by institutional investors.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.